NCT00138736View on ClinicalTrials.gov

Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

October 31, 2006

Conditions
MBL-DeficientNeutropenia
Interventions
DRUG

Mannan Binding Lectin (MBL)

DRUG

Mannan Binding Lectin

"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"

Trial Locations (2)

1105 AZ

Academic Medical Centre, Amsterdam

3015 GD

Erasmus Medical Centre, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Landsteiner Foundation for Blood Transfusion

OTHER

lead

Prothya Biosolutions

INDUSTRY